<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-3413</journal-id>
<journal-title><![CDATA[Arquivos de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Arq Med]]></abbrev-journal-title>
<issn>0871-3413</issn>
<publisher>
<publisher-name><![CDATA[ArquiMed - Edições Científicas AEFMUP ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-34132015000300002</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Hipotiroidismo subclínico, tiroidite autoimune e fatores de risco cardiovascular]]></article-title>
<article-title xml:lang="en"><![CDATA[Subclinical hypothyroidism, autoimmune thyroiditis and cardiovascular risk factor]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[Teresa Alves]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[Celestino]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esteves]]></surname>
<given-names><![CDATA[César]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[Davide]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[Luís]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[José Luís]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Serviço de Endocrinologia,Diabetes e Metabolismo  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Centro Hospitalar de São João Serviço e Laboratório de Imunologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2015</year>
</pub-date>
<volume>29</volume>
<numero>3</numero>
<fpage>69</fpage>
<lpage>73</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-34132015000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-34132015000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-34132015000300002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Introdução: Tem surgido evidência de que o hipotiroidismo subclínico se associa a um aumento do risco cardiovascular. O objetivo deste estudo foi avaliar as inter-relações entre tiroidite autoimune, hipotiroidismo subclínico e fatores de risco cardiovascular. Métodos: Analisámos a função tiroideia, anticorpos anti-TPO e antitiroglobulina, níveis de colesterol total, colesterol-HDL, colesterol-LDL, triglicerídeos, apolipoproteínaB, apolipoproteínaA1, lipoproteína(a), homocisteína, PCR de alta sensibilidade, ácido fólico, vitamina B12, HOMA-IR, HOMA-&#946;, QUICKI, HISI, WBISI, IGI em 185 doentes com tiroidite autoimune e eutiroidismo e em 69 doentes com tiroidite autoimune e hipotiroidismo subclínico. Para a análise estatística utilizámos o teste de Mann-Whitney, regressão logística e correlações de Spearman. Os resultados foram ajustados para a idade e índice de massa corporal. Considerou-se significativo um valor bilateral de p<0.05. Resultados: 94% dos indivíduos eram do sexo feminino. A mediana de idades foi significativamente superior no grupo eutiroideu. Valores de colesterol total (OR=1.01; p=0.03), PCR (OR=1.68; p=0.04) ou de anticorpos antitiroglobulina (OR=1.00; p=0.02) mais elevados associaram-me a maior probabilidade de sofrer de hipotiroidismo subclínico. No grupo total de doentes observaram-se correlações positivas entre TSH, PCR e HOMA-IR, entre T3 livre e colesterol-HDL e entre T4 livre e IGI. Os níveis de TSH correlacionaram-se negativamente com QUICKI, HISI e WBISI. No grupo com hipotiroidismo subclínico verificaram-se correlações negativas entre T3 livre e homocisteína e entre T4 livre e anticorpos anti-TPO. Conclusões: As inter-relações entre função tiroideia, PCR, perfil lipídico e insulinorresistência traduzem um aumento do risco cardiovascular no hipotiroidismo subclínico por tiroidite autoimune.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Background: There is increasing evidence that subclinical hypothyroidism is related with an increased cardiovascular risk. The objective was to evaluate the relationship between autoimmune thyroiditis, subclinical hypothyroidism and cardiovascular risk factors. Methods: We recorded thyroid function tests, anti-TPO and antithyroglobulin antibodies, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteinA1, apolipoproteinB, lipoprotein(a), homocysteine, high sensitivity CRP, folic acid, vitamin B12, HOMA-IR, HOMA-&#946;, QUICKI, HISI, WBISI, IGI in 185 subjects with autoimmune thyroiditis and in euthyroid state and in 69 subjects with autoimmune thyroiditis and subclinical hypothyroidism. Statistical analysis was performed with Mann-Whitney test, logistic regression and Spearman correlations. The results were adjusted for age and body mass index. Statistical significance was considered for a bilateral value of p<0.05. Results: 94% of subjects were female. The median age was significantly higher in the euthyroid group. Patients with higher levels of total cholesterol (OR=1.01; p=0.03), CRP (OR=1.68; p=0.04) or anti-thyroglobulin antibodies (OR=1.00; p=0.02) had an increased likelihood of having subclinical hypothyroidism. In the total group of patients, we observed positive correlations between TSH, CRP and HOMA-IR, between free T3 and HDL-cholesterol and between free T4 and IGI. TSH levels correlated negatively with QUICKI, HISI and WBISI. In the group with subclinical hypothyroidism, we found negative correlations between free T3 and homocysteine and between free T4 and anti-TPO antibodies. Conclusions: The interrelations between thyroid function, lipid profile, CRP and insulin-resistance demonstrate an increased cardiovascular risk in subclinical hypothyroidism due to autoimmune thyroiditis.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[hipotiroidismo]]></kwd>
<kwd lng="pt"><![CDATA[tiroidite autoimune]]></kwd>
<kwd lng="pt"><![CDATA[fatores de risco]]></kwd>
<kwd lng="pt"><![CDATA[doenças cardiovasculares]]></kwd>
<kwd lng="en"><![CDATA[hypothyroidism]]></kwd>
<kwd lng="en"><![CDATA[autoimmune thyroiditis]]></kwd>
<kwd lng="en"><![CDATA[risk factors]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular diseases]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b>INVESTIGAÇÃO ORIGINAL</b></p>     <p><b>Hipotiroidismo subclínico, tiroidite autoimune e fatores de risco cardiovascular</b></p>     <p><b>Subclinical hypothyroidism, autoimmune thyroiditis and cardiovascular risk factor </b></p>     <p><b>Teresa Alves Pereira<sup>3</sup>, Celestino Neves<sup>1,3</sup>, César Esteves<sup>1,3</sup>, Davide Carvalho<sup>1,3</sup>, Luís Delgado<sup>2,3</sup>, José Luís Medina<sup>3 </sup></b></p>     <p>&nbsp;</p>     <p><sup>1 </sup>Serviço de Endocrinologia,Diabetes e Metabolismo</p>     <p><sup>2 </sup>Serviço e Laboratório de Imunologia; Centro Hospitalar de São João</p>     <p><sup>3 </sup>Faculdade de Medicina da Universidade do Porto</p>     <p>&nbsp;</p>     <p> <a href="#c0">Correspondência</a><a name="topc0"></a></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><b>RESUMO </b></p>     <p>Introdução: Tem surgido evidência de que o hipotiroidismo subclínico se associa a um aumento do risco cardiovascular. O objetivo deste estudo foi avaliar as inter-relações entre tiroidite autoimune, hipotiroidismo subclínico e fatores de risco cardiovascular.</p>     <p>Métodos: Analisámos a função tiroideia, anticorpos anti-TPO e antitiroglobulina, níveis de colesterol total, colesterol-HDL, colesterol-LDL, triglicerídeos, apolipoproteínaB, apolipoproteínaA1, lipoproteína(a), homocisteína, PCR de alta sensibilidade, ácido fólico, vitamina B12, HOMA-IR, HOMA-&#946;, QUICKI, HISI, WBISI, IGI em 185 doentes com tiroidite autoimune e eutiroidismo e em 69 doentes com tiroidite autoimune e hipotiroidismo subclínico. Para a análise estatística utilizámos o teste de Mann-Whitney, regressão logística e correlações de Spearman. Os resultados foram ajustados para a idade e índice de massa corporal. Considerou-se significativo um valor bilateral de p&lt;0.05.</p>     <p>Resultados: 94% dos indivíduos eram do sexo feminino. A mediana de idades foi significativamente superior no grupo eutiroideu. Valores de colesterol total (OR=1.01; p=0.03), PCR (OR=1.68; p=0.04) ou de anticorpos antitiroglobulina (OR=1.00; p=0.02) mais elevados associaram-me a maior probabilidade de sofrer de hipotiroidismo subclínico. No grupo total de doentes observaram-se correlações positivas entre TSH, PCR e HOMA-IR, entre T3 livre e colesterol-HDL e entre T4 livre e IGI. Os níveis de TSH correlacionaram-se negativamente com QUICKI, HISI e WBISI. No grupo com hipotiroidismo subclínico verificaram-se correlações negativas entre T3 livre e homocisteína e entre T4 livre e anticorpos anti-TPO.</p>     <p>Conclusões: As inter-relações entre função tiroideia, PCR, perfil lipídico e insulinorresistência traduzem um aumento do risco cardiovascular no hipotiroidismo subclínico por tiroidite autoimune.</p>     <p><b>Palavras-chave:</b> hipotiroidismo, tiroidite autoimune, fatores de risco, doenças cardiovasculares</p>     <p>&nbsp;</p>     <p><b>ABSTRACT </b></p>     <p>Background: There is increasing evidence that subclinical hypothyroidism is related with an increased cardiovascular risk. The objective was to evaluate the relationship between autoimmune thyroiditis, subclinical hypothyroidism and cardiovascular risk factors.</p>     ]]></body>
<body><![CDATA[<p>Methods: We recorded thyroid function tests, anti-TPO and antithyroglobulin antibodies, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteinA1, apolipoproteinB, lipoprotein(a), homocysteine, high sensitivity CRP, folic acid, vitamin B12, HOMA-IR, HOMA-&#946;, QUICKI, HISI, WBISI, IGI in 185 subjects with autoimmune thyroiditis and in euthyroid state and in 69 subjects with autoimmune thyroiditis and subclinical hypothyroidism. Statistical analysis was performed with Mann-Whitney test, logistic regression and Spearman correlations. The results were adjusted for age and body mass index. Statistical significance was considered for a bilateral value of p&lt;0.05.</p>     <p>Results: 94% of subjects were female. The median age was significantly higher in the euthyroid group. Patients with higher levels of total cholesterol (OR=1.01; p=0.03), CRP (OR=1.68; p=0.04) or anti-thyroglobulin antibodies (OR=1.00; p=0.02) had an increased likelihood of having subclinical hypothyroidism. In the total group of patients, we observed positive correlations between TSH, CRP and HOMA-IR, between free T3 and HDL-cholesterol and between free T4 and IGI. TSH levels correlated negatively with QUICKI, HISI and WBISI. In the group with subclinical hypothyroidism, we found negative correlations between free T3 and homocysteine and between free T4 and anti-TPO antibodies.</p>     <p>Conclusions: The interrelations between thyroid function, lipid profile, CRP and insulin-resistance demonstrate an increased cardiovascular risk in subclinical hypothyroidism due to autoimmune thyroiditis.</p>     <p><b>Key-words:</b> hypothyroidism, autoimmune thyroiditis, risk factors, cardiovascular diseases</p>     <p>&nbsp;</p>     <p><b>Introdução</b></p>     <p>O hipotiroidismo subclínico, caracterizado pelo aumento dos níveis sanguíneos de tirotrofina (TSH) com manutenção de níveis de tiroxina livre (T4L) e de triiodotironina livre (T3L) normais, é um achado frequente na população geral, com uma prevalência estimada de 4 a 20%<sup>1</sup>. A prevalência é maior em mulheres e aumenta com a idade<sup>2</sup>. Cerca de 60-80% dos casos de hipotiroidismo subclínico associam-se a tiroidite linfocítica crónica (de Hashimoto), com anticorpos anti-peroxídase tiroideia (anti-TPO) positivos<sup>1</sup>.</p>     <p>O hipotiroidismo clinicamente manifesto (altos níveis sanguíneos de TSH associado sabaixos níveis de T4L e de T3L) tem sido forte mente associado a fatores de risco cardiovascular, como dislipidemia<sup>3</sup> e resistência à insulina<sup>4</sup>. Novos fatores de risco cardio vascular, como níveis plasmáticos de homocisteína edeproteína C reativa (PCR) aumentados, parecem também estar associados ao hipotiroidismo <sup>3,5,6</sup>.</p>     <p>Também para o hipotiroidismo subclínico tem surgido evidência de efeitos semelhantes sobre os fatores de risco cardiovascular, nomeadamente no que respeita ao perfil lipídico [aumento dos níveis plasmáticos de colesterol total e de colesterol-LDL<sup>7,8 </sup>e diminuição dos níveis de colesterol-HDL<sup>9</sup>], ao aumento dos níveis de insulinor resistência<sup>4</sup> e à presença de inflamação sistémica de baixo grau <sup>5,7</sup>. Alguns estudos reportam haver um aumento da concentração de lipoproteína (a) [(Lp(a)]10 e dos níveis de apolipoproteína B (ApoB)<sup>11</sup>.</p>     <p>No entanto, há estudos que referem que, apesar de existir uma relação significativa entre hipotiroidismo e dislipidemia, tal não se verifica para o hipotiroidismo subclínico<sup>12</sup>. Em relação aos novos fatores de risco cardiovascular, alguns estudos não encontraram diferenças significativas entre indivíduos eutiroideus e aqueles com hipotiroidismo subclínico no que respeita à concentração de homocisteína<sup>5,6,8 </sup>e de PCR<sup>8 </sup>nem no que respeita à insulinorresistência<sup>7,12</sup>.</p>     ]]></body>
<body><![CDATA[<p>Devido a estes dados ainda contraditórios em relação ao efeito do hipotiroidismo subclínico sobre os fatores de risco cardiovascular, permanece ainda alguma controvérsia acerca de quando rastrear e tratar estes casos de disfunção subclínica da tiroide. Recentemente, têm surgido estudos que demonstram existir uma relação entre valores de TSH no limite superior do normal e um perfillipídico desfavorável<sup>13</sup>. Outros estudos concluíram haver um risco aumentado de síndrome metabólica em doentes com TSH normal-alta<sup>14</sup>.</p>     <p>O objetivo deste estudo foi avaliar se o hipotiroidismo subclínico se associa à presença de fatores de risco cardiovascular, analisando o perfil lipídico, níveis de resistência à insulina, homocisteinemia e concentração sérica de PCR num grupo de doentes com tiroidite autoimune.</p>     <p>&nbsp;</p>     <p><b>Métodos </b></p>     <p>Amostra em estudo</p>     <p>Este foi um estudo transversal e retrospetivo, em que consultámos os processos clínicos de 254 doentes com tiroidite autoimune que recorreram à consulta externa de endocrinologia da nossa instituição,entre 2007 e 2010. Considerámos doentes com tiroidite autoimune aqueles com achados ecográficos característicos da tiroidite de Hashimoto e registos de valores plasmáticos de anticorpos anti-TPO superiores a 5.61 UI/ml e/ou valores de anticorpos antitiroglobulina (anti-tg) superiores a 4.11 UI/ml. foram excluídos doentes com outras doenças autoimunes, diabetes mellitus, patologia oncológica, eventos cardiovasculares prévios e a fazer medicação para dislipidemia ou doença tiroideia. Os doentes realizaram uma prova de tolerância à glicose oral (PTGO), com 75g de glicose, e efetuaram-se colheitas de sangue venoso de 30 em 30 minutos, durante 2 horas, para determinação da glicose, insulina epeptídeo-C.</p>     <p>Definição dos grupos</p>     <p>Considerou-se hipotiroidismo subclínico a partir de níveis de TSH de 2.5 µUI/ml, com os níveis de T3L considerados normais entre 1.71 e 3.71 pg/ml e de T4L entre 0.70 e 1.48 ng/dl. </p>     <p>Definimos dois grupos de doentes a comparar; no grupo 1, dos eutiroideus, incluímos os doentes com valores de TSH entre 0.35 e 2.5 µUI/ml, e com T4L e T3L dentro dos limites normais. No grupo 2, dos doentes com hipotiroidismo subclínico, incluímos os doentes com valores de TSH superiores 2.5 µUI/ ml, com T4L e T3L normais.</p>     <p>Análise dos dados</p>     ]]></body>
<body><![CDATA[<p>Com o teste de Mann-Whitney, comparámos a idade, o índice de massa corporal (IMC) e os níveis plasmáticos de TSH, T4L, T3L e de anticorpos antitg e anti-TPO. Para análise do risco cardiovascular, comparámos as seguintes variáveis: concentração plasmática de colesterol total, colesterol-LDL, colesterol-HDL, triglicerídeos, apolipoproteína A1 (ApoA1), ApoB, Lp(a), PCR de alta sensibilidade, homocisteína, vitamina B12, ácido fólico, <i>Homeostasis model assessment insulin resistance </i>(HOMA-IR)<sup>15</sup>, <i>Homeostasis model assessment &#946; cell </i>(HOMA-&#946;)<sup>15</sup>, <i>Insulinogenic index </i>(IGI)<sup>15</sup>, <i>Hepatic insulin sensitivity index </i>(HISI)<sup>16</sup>, <i>Whole body insulin sensitivity index </i>(WBISI) ou índice Matsuda<sup>17 </sup>e <i>Quantitative insulin sensitivity check index </i>(QUICKI)<sup>17</sup>. Os resultados foram expressos através da mediana e do intervalo interquartis (percentis 25 e 75).</p>     <p>Para determinar os fatores de risco para hipotiroidismo subclínico, foram calculados <i>odds ratio</i>s e os respetivos intervalos de confiança a 95% através da regressão logística, ajustando para a idade e IMC.</p>     <p>Foram ainda obtidas correlações de Spearman entre os valores de TSH, T3L e T4L e as variáveis de interesse, para o grupo total de indivíduos e para os grupos 1 e 2 separadamente.</p>     <p>Foi considerado significativo um valor bilateral de p &lt;0.05.</p>     <p>A análise foi efetuada utilizando o programa de análise estatística de dados SPSS® v.20.0 (<i>Statistical Package for the Social Sciences</i>).</p>     <p>O estudo teve a aprovação da Comissão de Ética da nossa instituição e os doentes deram o consentimento informado para participar no estudo.</p>     <p>&nbsp;</p>     <p><b>Resultados </b></p>     <p>No grupo 1, foram incluídos 185 indivíduos eutiroideus. No grupo 2 incluíram-se 69 doentes com hipotiroidismo subclínico. No total, 238participantes eram do sexo feminino, 16 do sexo masculino. A idade variou entre os 15 e os 81 anos e o IMC entre 16.26 e 41.62 kg/m<sup>2</sup>. A mediana de idade foi significativamente mais elevada no grupo 1 que no grupo 2 [49 (36-60) vs 42 (30-58) anos; p=0.03)] e o IMC semelhante [(26.56 (23.56-29.97) vs 25.51 (22.08-30.04) kg/m2; p=0.16)]. Os níveis de hormonas tiroideias dos dois grupos foram também semelhantes [T4L: 1.02 (0.94-1.13) vs 1.00 (0.91-1.10) ng/ dl, p=0.231; T3L: 2.73 (2.51-2.96) vs 2.85 (2.54-2.98) pg/ml,p=0.28]. As características dos indivíduos do estudo encontram-se descritas na <b><a href="#t1">Tabela 1</a></b>.</p>     <p>&nbsp;</p> <a name="t1"></a> <img src="/img/revistas/am/v29n3/29n3a02t1.jpg">     
]]></body>
<body><![CDATA[<p></p>     <p>&nbsp;</p>     <p>De entre os fatores de risco cardiovascular, apenas os valores de PCR estavam significativamente aumentados no grupo com hipotiroidismo subclínico relativamente ao grupo eutiroideu [0.335 (0.115-0.620) vs 0.180 (0.080-0.380) mg/dl; p=0.03]. As características dos grupos em termos de fatores de risco cardiovascular encontram-se descritas na <b><a href="#t2">Tabela 2</a></b>.</p>     <p>&nbsp;</p> <a name="t2"></a> <img src="/img/revistas/am/v29n3/29n3a02t2.jpg">     
<p></p>     <p>&nbsp;</p>     <p>Na análise efetuada com regressão logística, com ajuste para a idade e IMC, verificou-se que valores mais elevados de colesterol total (OR=1.01; p=0.03), PCR (OR=1.68; p=0.04) ou de anticorpos anti-tg (OR=1.00;p=0.02) se associavam a maior probabilidade de esses doentes apresentarem hipotiroidismo subclínico. Para as restantes variáveis não foram encontradas diferenças estatisticamente significativas. Os resultados da análise por regressão logística encontram-se descritos na <b><a href="#t3">Tabela 3</a></b>.</p>     <p>&nbsp;</p> <a name="t3"></a> <img src="/img/revistas/am/v29n3/29n3a02t3.jpg">     
<p></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p>Na análise com correlações de Spearman, verificou-se uma correlação estatisticamente significativa entre os níveis de colesterol-HDL e os de T3L, com um coeficiente de correlação de 0.16 (p=0.01) no grupo total de indivíduos do estudo. A correlação com significância estatística entre estas duas variáveis manteve-se no grupo eutiroideu (r = 0.17; p=0.03).</p>     <p>Também para a PCR foi encontrada uma correlação estatisticamente significativa com os níveis de TSH, no grupo total (r=0.13; p=0.04).</p>     <p>Obtiveram-se correlações estatisticamente significativas de vários marcadores de resistência à insulina com as variáveis independentes.</p>     <p>As correlações obtidas encontram-se descritas na <b><a href="/img/revistas/am/v29n3/29n3a02t4.jpg" target="_blank">Tabela 4</a></b>.</p>     
<p>&nbsp;</p>     <p><b>Discussão </b></p>     <p>Considerámos hipotiroidismo subclínico a partir de um valor de TSH de 2.5 µUI/ml, em vez dos valoresatuais de4ou5µUI/ml. Vários estudos encontraram valores populacionais médios de TSH próximos do limite inferior do intervalo considerado normal, nomeadamente o estudo de NHANES III, que obteve um valor médio de TSH da população norte-americana situado apenas entre 1.18 e 1.40 mUI/l<sup>2</sup>. Wartofsky et al. sugerem que se estabeleça um intervalo normal de TSH de 0.3 a 2.5µUI/ml; os indivíduos com valores superiores, que estes autores advogam apresentarem maior risco de evolução para hipotiroidismo, deverão ser seguidos de forma a detetar o desenvolvimento de disfunção clínica da tiroide e a iniciar o tratamento<sup>18</sup>.</p>     <p>Os resultados deste estudo mostram que níveis de colesterol total mais alto se associam a maior probabilidade de sofrer de hipotiroidismo subclínico. Um estudo demonstrou que mesmo indivíduos eutiroideus com TSH&gt;2.1µUI/ml apresentavam valores de colesterol total significativamente mais elevados que os indivíduos com TSH abaixo desse valor<sup>19</sup>. Outro estudo verificou que a concentração sérica de colesterol total estava significativamente mais elevada nos indivíduos com TSH no limite superior que nos indivíduos com TSH no limite inferior do normal<sup>20</sup>.</p>     <p>A PCR, que é um marcador de inflamação crónica de baixo grau, tem vindo a ser apontada como um fator de risco cardiovascular, uma vez que se considera que a aterosclerose é um processo inflamatório<sup>5</sup>. No nosso estudo verificámos que os doentes com valores mais altos de PCR apresentam maior probabilidade de sofrer de hipotiroidismo subclínico. Estes resultados estão em concordância com al-guns estudos<sup>5,7,21 </sup>que verificaram que doentes com hipotiroidismo subclínico apresentam níveis de PCR mais elevados, mas que, no entanto, consideraram hipotiroidismo subclínico a partir de valores de TSH de 4.2 µUI/ml ou de 5 µUI/ml.</p>     <p>Concluímos também que existe uma correlação positiva entre os níveis de TSH e os de PCR, ou seja, a PCR tende a aumentar com o aumento dos níveis de TSH.</p>     ]]></body>
<body><![CDATA[<p>Observámos ainda que doentes com níveis mais altos de anticorpos anti-tg apresentam maior risco de hipotiroidismo subclínico. Zhang et al. verificaram que, em doentes com tiroidite de Hashimoto, os níveis séricos de anticorpos anti-tg eram significativamente mais baixos em doentes eutiroideus do que nos doentes com hipotiroidismo clinicamente manifesto ou hipotiroidismo subclínico, e que estes, por sua vez, apresentavam valores significativamente inferiores aos dos doentes com hipotiroidismo clinicamente manifesto<sup>22</sup>. Türemen etal. chegaram a uma conclusão semelhante relativamente aos anticorpos anti-tg e anti-TPO<sup>21</sup>. No nosso estudo, verificámos a existênciade uma correlação negativa entre os anticorpos anti-TPO e os níveis de T4L no grupo de doentes com hipotiroidismo subclínico, o que sugere que níveis mais elevados de anticorpos anti-TPO poderão estar associados a menor produção de T4L, por via da maior agressão autoimune e maior destruição celular.</p>     <p>Também para o colesterol-HDL obtivemos uma correlação positiva com os níveis de T3L, tanto no grupo total como no grupo eutiroideu. A T3 estimula a síntese e a atividade dos recetores de colesterol-LDL hepáticos e periféricos, o que aumenta a depuração das partículas LDL. Concomitantemente, parece aumentar a concentração sérica de colesterol-HDL através da indução da atividade da ApoA1, que é a lipoproteína encontrada em maior quantidade na partícula de colesterol-HDL<sup>23</sup>. Alguns estudos observaram uma relação inversa entre os níveis de TSH e de colesterol-HDL<sup>24 </sup>e outros uma relação positiva entre a T4L e o colesterol-HDL<sup>25,26</sup>.</p>     <p>No que respeita aos marcadores de resistência à insulina, verificámos uma correlação positiva entre o HOMA-IR e a TSH, enquanto que, para os marcadores de sensibilidade à insulina QUICKI, HISI e WBISI, obtivemos uma correlação negativa com a TSH no grupo total de participantes do estudo. Ainda que não apresentem fortes coeficientes de correlação, as correlações obtidas permitem-nos concluir que o hipotiroidismo subclínico se associa a um estado aumentado de insulinorresistência. Também Vyakaranam et al. demonstraram que indivíduos com hipotiroidismo subclínico apresentavam valores mais elevados de HOMA-IR do que os eutiroideus<sup>27</sup>. Garduño-Garcia et al. verificaram que uma maior concentração plasmática de TSH, mesmo que dentro do limite normal, predispõe a níveis de HOMA-IR aumentados<sup>25</sup>; Roos et al. concluiram ainda que,mesmo ligeiras diminuições nas concentrações de hormonas tiroideias, dentro dos limites normais, estavam relacionadas com um aumento do HOMA-IR<sup>26</sup>.</p>     <p>No estudo de Maratou et al., o WBISI estava significativamente diminuído em doentes com hipotiroidismo e com hipotiroidismo subclínico<sup>4</sup>. estes autores demonstraram ainda que o transporte de glicose mediado pela insulina, em monócitos de doentes com hipotiroidismo e com hipotiroidismo subclínico, estava reduzido, em consequência da diminuição da translocação de GLUT4 para a membrana celular, sugerindo que o mesmo se passa nos tecidos muscular e adiposo<sup>4</sup>.</p>     <p>No nosso estudo, o IGI, um índice de função das células &#946;, correlacionou-se positivamente com a T4L no grupo total de participantes e no grupo eutiroideu, o que sugere que com o aumento dos níveis de T4L tenderá a existir uma maior produção de insulina pelas células &#946;.</p>     <p>Obtivemos ainda, no grupo com hipotiroidismo subclínico, uma correlação negativa do QUICKI e HISI com a T3L e positivado HOMA-IR com a T3L.</p>     <p>De facto, a maioria das ações metabólicas desempenhadas pelas hormonas tiroideias é exercida pela T3; no entanto, as enzimas responsáveis pela síntese da T3, as deiodinases 1 e 2, existem em muitos outros tecidos além da tiroide e contribuem também para os níveis séricos de T3<sup>28</sup>. Assim, existe o consenso de que os níveis de T3L, dentro dos limites normais, não apresentam uma relação clara com a função tiroideia<sup>26</sup>.</p>     <p>Observámos uma relação inversa estatisticamente significativa entre os níveis sanguíneos de homocisteína e os de T3L, no grupo com hipotiroidismo subclínico. A hiperhomocisteinemia constitui um importante fator de risco cardiovascular ao predispor a lesão endotelial, stress oxidativo, hipertrofia do músculo liso vascular e a oxidação das partículas de colesterol-LDL<sup>29</sup>. Orzechowska-Pawilojc et al. concluiram que os níveis plasmáticos de hormonas tiroideias e de TSH são determinantes importantes da concentração sanguínea de homocisteína<sup>29</sup>. No nosso estudo comparámos também as concentrações séricas de vitamina B12 e de ácido fólico nos dois grupos, uma vez que os níveis de homocisteína são influenciados por estas variáveis, mas não obtivemos diferenças estatisticamente significativas.</p>     <p>Uma limitação do nosso estudo é o seu desenho transversal, que apenas permite estabelecer associações entre os fatores de risco cardiovascular e a função tiroideia e não uma relação de causa-efeito. O tamanho da amostra pode constituir uma limitação, não permitindo encontrar mais associações significativas entre a função tiroideia e as variáveis de interesse.</p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><b>Agradecimentos </b></p>     <p>Os autores agradecem à Dr.ª Cláudia Camila Dias do Departamento de Ciências da Informação e da Decisão em Saúde da faculdade de Medicina da Universidade do Porto a ajuda na elaboração da análise estatística.</p>     <p>&nbsp;</p>     <p><b>Referências </b></p>     <!-- ref --><p>1. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012; 379: 1142&#8211;54.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000087&pid=S0871-3413201500030000200001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>2. Hollowell JG, Staehling NW, flanders WD, Hannon WH, Gunter EW, Spencer CA et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition examination Survey (NHANES III). J Clin endocrinol Metab. 2002; 87: 489-99.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000089&pid=S0871-3413201500030000200002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>3. Neves C, Alves M, Medina JL, Delgado JL. Doenças da tireóide, dislipidemia e patologia cardiovascular. Rev Port Cardiol. 2008; 27: 1211-36.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000091&pid=S0871-3413201500030000200003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>4. Maratou E, Hadjidakis DJ, Kollias A. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009; 160: 785-90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000093&pid=S0871-3413201500030000200004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>5. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub J-J et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003; 166: 379-86.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000095&pid=S0871-3413201500030000200005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>6. Zhou Y, Chen Y, Cao X, Liu C, Xie Y. Association between plasma homocysteine status and hypothyroidism: a meta-analysis. Int J Clin Exp Med. 2014; 7(11): 4544-53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000097&pid=S0871-3413201500030000200006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>7. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J. 2005; 52: 89-94.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000099&pid=S0871-3413201500030000200007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>8. Toruner F, Altinova AE, Karakoc A, Yetkin I, Ayvaz G, Cakir N et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Adv Ther. 2008; 25: 430-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000101&pid=S0871-3413201500030000200008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>9. Hernández-Mijares A, Jover A, Bellod L, Bañuls C, Solá E, Veses S et al. Relation between lipoprotein subfractions and TSH levels in the cardiovascular risk among women with subclinical hypothyroidism. Clin Endocrinol. 2013; 78: 777-82.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000103&pid=S0871-3413201500030000200009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>10. Lee W-Y,Suh J-Y, Rheee-J, Park J-S, Sung K-C, Kim S-W. Plasma CRP, Apolipoprotein A-1, Apolipoprotein BandL p(a) Levels According to Thyroid function Status. Arch Med Res. 2004; 35: 540-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000105&pid=S0871-3413201500030000200010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>11. Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktarie T, Elisaf MS et al. Lipid profile insub clinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol. 2001; 145: 705-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000107&pid=S0871-3413201500030000200011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>12. Al-Tonsi AA, Abdel-Gayoum AA, Saad M. The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders. Exp Mol Pathol. 2004; 76: 182-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000109&pid=S0871-3413201500030000200012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>13. Asvold BO, Vatten LJ, Nilsen TIL, Bjøro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156: 181&#8211;6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000111&pid=S0871-3413201500030000200013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>14. Ruhla S, Weickert MO, Arafat AM, Osterhoff M, Isken F, Spranger J et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf). 2012; 72: 696-701.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000113&pid=S0871-3413201500030000200014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>15. Lorenzo C, Hazuda HP, Haffner SM. Insulin Resistance and excess Risk of Diabetes in Mexican-Americans: The San Antonio Heart Study. J Clin endocrinol Metab. 2012; 97: 793&#8211;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000115&pid=S0871-3413201500030000200015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>16. Turner R, Holman R, Matthews D, Hockaday T, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism. 1979; 28: 1086&#8211;96.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000117&pid=S0871-3413201500030000200016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>17. Lorenzo C, Haffner SM, Stancáková A, Laakso M. Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish off spring of type 2 diabetic Individuals. J Clin Endocrinol Metab. 2010; 95(11): 5082-90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000119&pid=S0871-3413201500030000200017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>18. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin endocrinol Metab. 2005; 90: 5483&#8211;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000121&pid=S0871-3413201500030000200018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>19. Boggio A, Muzio F, Fiscella M, Sommariva D, Branchi A. Is thyroid-stimulating hormone with in the normal reference range a risk factor for atherosclerosis in women? Intern Emerg Med. 2014;9:51-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000123&pid=S0871-3413201500030000200019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>20. Wanjia X, Chenggang W, Aihong W, Xiaomei Y, Jiajun Z, Chunxiao Y et al. A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease. Lipids Health Dis. 2012; 11: 44.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000125&pid=S0871-3413201500030000200020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>21. Türemen EE, Çetinarslan B, &#350;ahin T, Cantürk Z, Tarkun &#304;. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J. 2011; 58: 349-54.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000127&pid=S0871-3413201500030000200021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>22. Zhang Y, Gao Y, Li M, Xie L, Huang Y, Gao Y et al. Avidity of thyroglobulin antibody in sera from patients with Hashimoto's thyroiditis with different thyroid functional status. Clin Exp Immunol. 2010; 161: 65-70.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000129&pid=S0871-3413201500030000200022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>23. Ness GC, Lopez D, Chambers CM, Newsome WP, Cornelius P, Long CA et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and Apo A-I gene expression. Biochem Pharmacol. 1998; 56: 121-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000131&pid=S0871-3413201500030000200023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>24. Rondeaua G, Rutamucerob N, Messierb V, Burlacud L, Prud'hommed D, Mircescua H et al. Reference range thyroid-stimulating hormone is associated with physical activity energy expenditure in overweight and obese postmenopausal women: a Montreal-Ottawa New emerging Team Study. Metabolism. 2010; 59: 1597&#8211;602.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000133&pid=S0871-3413201500030000200024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>25. Garduño-Garcia JDJ, Alvirde-Garcia U, López-Carrasco G, Mendoza MEP, Mehta R, Arellano-Campos O et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol. 2010; 163: 273-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000135&pid=S0871-3413201500030000200025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>26. Roos A, Bakker SJL, Links TP, Gans ROB, Wolffenbuttel BHR. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007; 92: 491-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000137&pid=S0871-3413201500030000200026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>27. Vyakaranam S, Vanaparthy S, Nori S, Palarapu S, Bhongir AV. Study of Insulin Resistance in Subclinical Hypothyroidism. Int J Health Sci Res. 2014; 4(9): 147&#8211;53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000139&pid=S0871-3413201500030000200027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>28. Köhrle J. Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination. Best Pract Res Clin endocrinol Metab. 2007; 21: 173&#8211;91.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000141&pid=S0871-3413201500030000200028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>29. Orzechowska-Pawilojc A, Sworczak K, Lewczuk A, Babinska A. Homocysteine, folate and cobalamine levels in hypothyroid women before and after treatment. Endocr J. 2007; 54: 471-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000143&pid=S0871-3413201500030000200029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>&nbsp;</p>     <p><a href="#topc0">Correspondência:</a><a name="c0"></a></p>     <p><b>Teresa Alves Pereira </b></p>     <p>Serviço de endocrinologia, Faculdade de Medicina da Universidade do Porto. Alameda Professor Hernâni Monteiro -4200-319 Porto. <i>E-mail:</i> <a href="mailto:teresa.pereira488@gmail.com">teresa.pereira488@gmail.com</a></p>     <p>&nbsp;</p>     <p><b>Data de recepção / reception date: 30-01-2015</b></p>     <p><b>Data de aprovação / approval date: 17-03-2015 </b></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Subclinical thyroid disease]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>379</volume>
<page-range>1142-54</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollowell]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Staehling]]></surname>
<given-names><![CDATA[NW]]></given-names>
</name>
<name>
<surname><![CDATA[flanders]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Hannon]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Gunter]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition examination Survey (NHANES III)]]></article-title>
<source><![CDATA[J Clin endocrinol Metab]]></source>
<year>2002</year>
<volume>87</volume>
<page-range>489-99</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Doenças da tireóide, dislipidemia e patologia cardiovascular]]></article-title>
<source><![CDATA[Rev Port Cardiol]]></source>
<year>2008</year>
<volume>27</volume>
<page-range>1211-36</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maratou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hadjidakis]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kollias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Studies of insulin resistance in patients with clinical and subclinical hypothyroidism]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2009</year>
<volume>160</volume>
<page-range>785-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christ-Crain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guglielmetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Riesen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Staub]]></surname>
<given-names><![CDATA[J-J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism?: A cross-sectional and a double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2003</year>
<volume>166</volume>
<page-range>379-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association between plasma homocysteine status and hypothyroidism: a meta-analysis]]></article-title>
<source><![CDATA[Int J Clin Exp Med]]></source>
<year>2014</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4544-53</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bahceci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gokalp]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Y]]></surname>
<given-names><![CDATA[Tuzun]]></given-names>
</name>
<name>
<surname><![CDATA[Gunes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia]]></article-title>
<source><![CDATA[Endocr J]]></source>
<year>2005</year>
<volume>52</volume>
<page-range>89-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toruner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Altinova]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Karakoc]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yetkin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ayvaz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk factors for cardiovascular disease in patients with subclinical hypothyroidism]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2008</year>
<volume>25</volume>
<page-range>430-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Mijares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jover]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bellod]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bañuls]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Solá]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Veses]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Relation between lipoprotein subfractions and TSH levels in the cardiovascular risk among women with subclinical hypothyroidism]]></article-title>
<source><![CDATA[Clin Endocrinol]]></source>
<year>2013</year>
<volume>78</volume>
<page-range>777-82</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[W-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suh]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rhee]]></surname>
<given-names><![CDATA[E-J]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J-S]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[K-C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S-W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Plasma CRP, Apolipoprotein A-1, Apolipoprotein BandL p(a) Levels According to Thyroid function Status]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2004</year>
<volume>35</volume>
<page-range>540-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Efstathiadou]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bitsis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Milionis]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kukuvitis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bairaktarie]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Elisaf]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lipid profile insub clinical hypothyroidism: is L-thyroxine substitution beneficial?]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2001</year>
<volume>145</volume>
<page-range>705-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Tonsi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Gayoum]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders]]></article-title>
<source><![CDATA[Exp Mol Pathol]]></source>
<year>2004</year>
<volume>76</volume>
<page-range>182-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asvold]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Vatten]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsen]]></surname>
<given-names><![CDATA[TIL]]></given-names>
</name>
<name>
<surname><![CDATA[Bjøro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The association between TSH within the reference range and serum lipid concentrations in a population-based study: The HUNT Study]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2007</year>
<volume>156</volume>
<page-range>181-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruhla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weickert]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Arafat]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Osterhoff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isken]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Spranger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A high normal TSH is associated with the metabolic syndrome]]></article-title>
<source><![CDATA[Clin Endocrinol (Oxf)]]></source>
<year>2012</year>
<volume>72</volume>
<page-range>696-701</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hazuda]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Insulin Resistance and excess Risk of Diabetes in Mexican-Americans: The San Antonio Heart Study]]></article-title>
<source><![CDATA[J Clin endocrinol Metab]]></source>
<year>2012</year>
<volume>97</volume>
<page-range>793-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Holman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hockaday]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>1979</year>
<volume>28</volume>
<page-range>1086-96</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Stancáková]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laakso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish off spring of type 2 diabetic Individuals]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2010</year>
<volume>95</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>5082-90</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wartofsky]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dickey]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The evidence for a narrower thyrotropin reference range is compelling]]></article-title>
<source><![CDATA[J Clin endocrinol Metab]]></source>
<year>2005</year>
<volume>90</volume>
<page-range>5483-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boggio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muzio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fiscella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sommariva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Branchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is thyroid-stimulating hormone with in the normal reference range a risk factor for atherosclerosis in women?]]></article-title>
<source><![CDATA[Intern Emerg Med]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>51-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanjia]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chenggang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Aihong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Xiaomei]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jiajun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease]]></article-title>
<source><![CDATA[Lipids Health Dis]]></source>
<year>2012</year>
<volume>11</volume>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Türemen]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Çetinarslan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[&#350;ahin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cantürk]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Tarkun]]></surname>
<given-names><![CDATA[&#304;]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis]]></article-title>
<source><![CDATA[Endocr J]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>349-54</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Avidity of thyroglobulin antibody in sera from patients with Hashimoto's thyroiditis with different thyroid functional status]]></article-title>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2010</year>
<volume>161</volume>
<page-range>65-70</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ness]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chambers]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Newsome]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Cornelius]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and Apo A-I gene expression]]></article-title>
<source><![CDATA[Biochem Pharmacol]]></source>
<year>1998</year>
<volume>56</volume>
<page-range>121-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rondeaua]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rutamucerob]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Messierb]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Burlacud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prud'hommed]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reference range thyroid-stimulating hormone is associated with physical activity energy expenditure in overweight and obese postmenopausal women: a Montreal-Ottawa New emerging Team Study]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>2010</year>
<volume>59</volume>
<page-range>1597-602</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garduño-Garcia]]></surname>
<given-names><![CDATA[JDJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alvirde-Garcia]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[López-Carrasco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[MEP]]></surname>
<given-names><![CDATA[Mendoza]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arellano-Campos]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2010</year>
<volume>163</volume>
<page-range>273-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[SJL]]></given-names>
</name>
<name>
<surname><![CDATA[Links]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Gans]]></surname>
<given-names><![CDATA[ROB]]></given-names>
</name>
<name>
<surname><![CDATA[Wolffenbuttel]]></surname>
<given-names><![CDATA[BHR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2007</year>
<volume>92</volume>
<page-range>491-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vyakaranam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vanaparthy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palarapu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhongir]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Study of Insulin Resistance in Subclinical Hypothyroidism]]></article-title>
<source><![CDATA[Int J Health Sci Res]]></source>
<year>2014</year>
<volume>4</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>147-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Köhrle]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination]]></article-title>
<source><![CDATA[Best Pract Res Clin endocrinol Metab]]></source>
<year>2007</year>
<volume>21</volume>
<page-range>173-91</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orzechowska-Pawilojc]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sworczak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lewczuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Babinska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Homocysteine, folate and cobalamine levels in hypothyroid women before and after treatment]]></article-title>
<source><![CDATA[Endocr J]]></source>
<year>2007</year>
<volume>54</volume>
<page-range>471-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
